Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1' -cyclohexane]platinum(II) in dogs

A pharmacokinetic study on cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2- spiro-1'-cyclohexane]platinum(II) (SKI 2032R) was performed in dogs. A single dose of 2.0 mg/kg of SKI 2032R was administered i.v. bolus to three beagle dogs. Plasma samples were analyzed for platinum by flameless atomic absorption spectrophotometry. Plasma concentrations of total and ultrafiltrable platinum for SKI 2032R declined in a biexponential fashion. The mean area under the concentration-time curve (AUC(0→∞) determined for ultrafiltrable platinum derived from SKI 2032R, as an active component, was 2.36 ± 0.23 μg·h/ml (mean ± S.D.), with an initial half-life of 0.23 ± 0.20 hour, a terminal half-life of 1.32 ± 0.49 hour, a total clearance of 14.17 ± 1.50 ml/min/kg, and a steady-state volume of distribution of 1.21 ± 0.24 l/kg.